HIGHLIGHTS
- who: Shelby M. Knoche et al. from the Eppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, University have published the research: The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer, in the Journal: PLOS ONE of September/20,/2022
- what: The authors demonstrated that an HDAC is efficacious against pancreatic cancer in vitro and in vivo alone or with gemcitabine. The authors demonstrated that M344 treatment of pancreatic cancer cells significantly reduces their proliferation and viability and greatly diminishes their ability to migrate.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.